Review summarizes advancements in tumor-targeting strategies for PLGA-based nanoparticles, suggesting new research opportunities.
Poly(lactic‐co‐glycolic acid) (PLGA) is an FDA‐approved polymer for its biocompatibility and biodegradability. PLGA‐based nanoparticles (NPs) are well recognized as promising candidates for drug delivery. However, the lack of selectivity to cancer cells limits the clinical application of PLGA‐based NPs. In recent years, a number of studies were focused on tackling this limitation and showed great potential in improving the anticancer efficacy. Herein, we summarize passive tumor‐targeting strategies through the EPR effect and active tumor‐targeting strategies through ligand modifications based on PLGA NPs for tumor‐targeted drug delivery. Finally, new challenges and possible opportunities for further research are also discussed.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: